1. Home
  2. FRSH vs AUPH Comparison

FRSH vs AUPH Comparison

Compare FRSH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshworks Inc.

FRSH

Freshworks Inc.

HOLD

Current Price

$9.35

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.86

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRSH
AUPH
Founded
2010
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
FRSH
AUPH
Price
$9.35
$15.86
Analyst Decision
Buy
Buy
Analyst Count
15
4
Target Price
$14.86
$17.25
AVG Volume (30 Days)
12.0M
1.1M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
296.88
5075.00
EPS
N/A
0.25
Revenue
$838,809,000.00
$283,055,000.00
Revenue This Year
$16.30
$17.54
Revenue Next Year
$14.09
$15.74
P/E Ratio
N/A
$63.40
Revenue Growth
16.43
20.38
52 Week Low
$6.79
$7.29
52 Week High
$15.51
$16.88

Technical Indicators

Market Signals
Indicator
FRSH
AUPH
Relative Strength Index (RSI) 52.15 53.16
Support Level $7.71 $14.60
Resistance Level $9.40 $16.38
Average True Range (ATR) 0.43 0.54
MACD -0.06 0.03
Stochastic Oscillator 22.16 52.17

Price Performance

Historical Comparison
FRSH
AUPH

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: